Cargando…

Flow-Cytometry Platform for Intracellular Detection of FVIII in Blood Cells: A New Tool to Assess Gene Therapy Efficiency for Hemophilia A

Detection of factor VIII (FVIII) in cells by flow cytometry is controversial, and no monoclonal fluorescent antibody is commercially available. In this study, we optimized such an assay and successfully used it as a platform to study the functional properties of phosphoglycerate kinase (PGK)-FVIII l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elnaggar, Muhammad, Al-Mohannadi, Anjud, Kizhakayil, Dhanya, Raynaud, Christophe Michel, Al-Mannai, Sharefa, Gentilcore, Giusy, Pavlovski, Igor, Sathappan, Abbirami, Van Panhuys, Nicholas, Borsotti, Chiara, Follenzi, Antonia, Grivel, Jean-Charles, Deola, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920166/ https://www.ncbi.nlm.nih.gov/pubmed/31886317 http://dx.doi.org/10.1016/j.omtm.2019.11.003

Ejemplares similares

CD14(+)/CD31(+) monocytes expanded by UM171 correct hemophilia A in zebrafish upon lentiviral gene transfer of factor VIII
por: Elnaggar, Muhammad, et al.
Publicado: (2022)

Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
por: Afraz, Sajjad, et al.
Publicado: (2022)

Recombinant FVIII: the milestone of modern hemophilia treatment
por: Mannucci, Pier Mannuccio
Publicado: (2023)

Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII
por: Nguyen, S., et al.
Publicado: (2019)

Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs
por: Sung, Jin Jea, et al.
Publicado: (2019)

Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
por: Mancuso, Maria Elisa, et al.
Publicado: (2014)

Prevalence of FVIII Inhibitors Among Children with Hemophilia A: Experience at the Jordanian Royal Medical Services
por: Oudat, Raida, et al.
Publicado: (2020)

Proceedings From the First International Workshop at Sidra Medicine: “Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development”, 15(th)–16(th) February 2019, Doha, Qatar
por: Guerrouahen, Bella, et al.
Publicado: (2021)

In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A
por: Hemşinlioğlu, Cansu, et al.
Publicado: (2023)

Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII
por: Hooimeijer, Louise H, et al.
Publicado: (2023)

Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients
por: Abolghasemi, Hassan, et al.
Publicado: (2018)

Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors
por: Schweiger, Helmut, et al.
Publicado: (2022)

Synthesis of FVIII in Hemophilia-A patients with the intron-22-inversion may modulate immunogenicity
por: Pandey, Gouri Shankar, et al.
Publicado: (2013)

FVIII Immunogenicity—Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A
por: Hart, Daniel P.
Publicado: (2020)

The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A
por: Kim, Ju Young, et al.
Publicado: (2019)

The dataset from administration of single or combined immunomodulation agents to modulate anti-FVIII antibody responses in FVIII plasmid or protein primed hemophilia A mice
por: Liu, Chao Lien, et al.
Publicado: (2016)

Tailoring cells for clinical needs: Meeting report from the Advanced Therapy in Healthcare symposium (October 28–29 2017, Doha, Qatar)
por: Deola, Sara, et al.
Publicado: (2018)

Functional Characterization of the MYO6 Variant p.E60Q in Non-Syndromic Hearing Loss Patients
por: Alkowari, Moza, et al.
Publicado: (2022)

Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies
por: Pittari, Gianfranco, et al.
Publicado: (2015)

Identification of FVIII gene mutations in patients with hemophilia A using new combinatorial sequencing by hybridization
por: Chetta, M., et al.
Publicado: (2008)

Development of an FVIII Inhibitor in a Mild Hemophilia Patient with a Phe595Cys Mutation
por: Yamanouchi, Jun, et al.
Publicado: (2018)

Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A
por: Cai, Yuanhua, et al.
Publicado: (2020)

Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A
por: El-Akabawy, Nadia, et al.
Publicado: (2020)

The Possible Non-Mutational Causes of FVIII Deficiency: Non-Coding RNAs and Acquired Hemophilia A
por: Zimta, Alina-Andreea, et al.
Publicado: (2021)

Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1(+) Tregs
por: Becker-Gotot, Janine, et al.
Publicado: (2022)

Escape or Fight: Inhibitors in Hemophilia A
por: Merlin, Simone, et al.
Publicado: (2020)

Therapeutic potential of fetal liver cell transplantation in hemophilia A mice
por: Merlin, Simone, et al.
Publicado: (2023)

Association of Genetic Variant FVIII Gene and Factor VIII: A Pilot Study Among Hemophilia A Female Relatives in Saudi Arabia
por: Almohammadi, Abdullah T, et al.
Publicado: (2023)

Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A
por: Lytle, Allison M, et al.
Publicado: (2016)

Effects of Shear Stress on Production of FVIII and vWF in a Cell-Based Therapeutic for Hemophilia A
por: Trevisan, Brady, et al.
Publicado: (2021)

Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A
por: Elkouby, Liron, et al.
Publicado: (2021)

Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A
por: Ai, Di, et al.
Publicado: (2022)

Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication
por: Paul, Helmut, et al.
Publicado: (2022)

A graph-based machine learning framework identifies critical properties of FVIII that lead to hemophilia A
por: Ferreira, Marcos V., et al.
Publicado: (2023)

Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2
por: Chouchane, Lotfi, et al.
Publicado: (2021)

Successful Perioperative Combination of High-Dose FVIII Therapy Followed by Emicizumab in a Patient with Hemophilia A with Inhibitors
por: Okamoto, Shuichi, et al.
Publicado: (2019)

The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice.
por: Bou-Jaoudeh, Melissa, et al.
Publicado: (2023)

Limited Generalizability of a Retrospective Chart Review Comparing 3 Recombinant FVIII Products for Hemophilia A Prophylaxis
por: Preblick, Ronald, et al.
Publicado: (2020)

Emerging Therapeutic Approaches for Diamond Blackfan Anemia
por: Aspesi, Anna, et al.
Publicado: (2018)

Paracrine Mechanisms of Mesenchymal Stromal Cells in Angiogenesis
por: Maacha, Selma, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_eb7t6qqt0d3hi602b8i7jh0nue